An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

Boehringer Ingelheim

Status

Conditions: Lung Diseases, Interstitial

Treatments: Drug: OFEV

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03843892

1199-0380

Details and patient eligibility

About

This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

None

Exclusion criteria

• Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).